Imaging beyond the striatonigral dopaminergic system in Parkinson's disease

Hellenic Journal of Nuclear Medicine

Volumn 15, Issue 3, 2012, Pages

  Giza, Evangelia ^a   Gotzamani Psarrakou, Anna ^a   Bostantjopoulou, Sevasti ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

123I MIBG scintigraphy; Diagnosis by PET; Diagnosis by SPET; Microglial activation; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NEUROTRANSMITTER; SEROTONIN TRANSPORTER;

CELL ACTIVATION; CHOLINERGIC SYSTEM; DENERVATION; DOPAMINERGIC SYSTEM; HEART SCINTISCANNING; HUMAN; MICROGLIA; NORADRENERGIC SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC NERVE;

CORPUS STRIATUM; DOPAMINERGIC NEURONS; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84871892910     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1-14. (Pubitemid 36793796)
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and treatment. Lancet Neurol 2006; 2006; 5: 235-45. (Pubitemid 43238347)
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and management. Lancet Neurol 2009; 8: 464-74.
4. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 2010; 17: 364-76.
5. Bloch A, Probst A, Bissig H et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006; 32: 284-95.
6. Klos KJ, Ahlsklog JE, Josephs KA et al. a-Synuclein pathology in the spinal cord of neurologically asymptomatic aged individuals. Neurology 2006; 66: 1100-2. (Pubitemid 44044801)
7. Braak H, Sastre M, BohI JRE et al. Parkinson's disease: lesions in the dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421-9. (Pubitemid 46421631)
8. Breen DP, Michell AW, Barker RA. Parkinson's disease-the continuing search for biomarkers. Clin Chem Lab Med 2011; 49: 393-401.
9. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011; 68: 22-30.
10. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009; 72Suppl 2: S21-6.
11. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 722-9.
12. Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007; 22: 1229-38. (Pubitemid 47325028)
13. Gardner EL, Ashby CR. Heterogeneity of mesotelencephalic dopamine fibers: physiology and pharmacology. Neurosci Behav Rev 2000; 24: 115-8. (Pubitemid 30026152)
14. Sasaki M, Shibata E, Tohyama K et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport 2008; 19: 1649-54.
15. ndedn. Oxford, Wiley-Blackwell 2011; 194-223.
16. 18F]Fluorodopa studies correlate with dopamine cell counts and levels. Ann Neural 1993; 34: 324-30.
17. 18F]fluoro-Dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993; 13: 43-56.
18. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin 2001; 31: 321-40. (Pubitemid 33054611)
19. 18F] fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 2005; 26: 891-8.
20. 18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001; 124: 1125-30.
21. Rakshi JS, Uema T, Ito K et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study. Brain 1999; 122: 1637-50. (Pubitemid 29425668)
22. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neural 2003: 53: 206-13. (Pubitemid 36164002)
23. 18F]Fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006; 21: 958-63.
24. Ouchi Y, Yoshikawa E, Okada H et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for β-CFT binding with positron emission tomography. Ann Neural 1999; 45: 601-10. (Pubitemid 29217588)
25. 18F-dopa PET study. Neurobiol Dis 2008; 29: 381-90.
26. 18F] Fluorodopa positron emission tomographic study. Arch Neurol 2000; 57: 470-5.
27. Klein JC, Eggers C, Kalbe E et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-92.
28. Ito K, Nagano-Saito A, Kato T et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 1358-65. (Pubitemid 34587144)
29. Kaasinen V, Nagren K, Hietala J et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000; 54: 1482-87. (Pubitemid 30210470)
30. Kaasinen V, Aalto S, Nagren K et al. Extrastriatal dopamine D2 receptors in Parkinson's disease: a longitudinal study. J Neural Transm 2003; 110: 591-601. (Pubitemid 36683513)
31. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331-43.
32. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 2003; 91: 39-49.
33. 123I]β-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001; 16: 124-30.
34. 123FP-CIT SPECT study. Mov Disord 2010; 25: 1853-9.
35. 123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005; 128: 1605-12.
36. 11C]DASB PET study in Parkinson's disease. Neuroimage 2012; 59: 1080-4.
37. Albin RL, Koeppe RA, Bohnen NI et al. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cerebr Blood Flow Metab 2008; 28: 441-4. (Pubitemid 351304276)
38. 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-21.
39. 123I]-ADAM SPECT study. Eur J Neurol 2011; 18: 750-55.
40. Strecker K, Wegner F, Hesse S et al. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with dopamine transporter. J Neurol 2011; 258: 19-26.
41. Guttman M, Boileau I, Warsh J et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Nucl Med 2007; 14: 523-28. (Pubitemid 46587839)
42. 123I-β-CIT SPECT.J Nucl Med 2003; 44: 870-6.
43. 123] β-CIT SPECT study. J Neural Transm 2008; 115: 721-9.
44. 11C] DASB. Mov Disord 2008; 23: 1776-80.
45. Politis M, Wu K, Loane C et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010; 75: 1920-27.
46. Pavese N, Metta V, Bose SK et al. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133: 3434-43.
47. Doder M, Rabiner EA, Turjanski N et al. Tremor in Parkinson's disease and serotonergic function dysfunction. An 11C-WAY 100635 PET study. Neurology 2003; 60: 601-5. (Pubitemid 36246076)
48. Ballanger B, Klinger H, Eche J et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 2012; 27: 84-9.
49. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organization. Curr Neuropharmacol 2008; 6: 235-53.
50. Braak H, Del Tredici K, Rób H et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
51. Isaias IU, Marotta G, Pezzoli G et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurology 2011; 11: 88-94.
52. 18F-dopa PET study. Neuroimage 2011; 56: 1463-8.
53. Lewis Si, Pavese N, Rivero-Bosch M et al. Brain monoamine systems in multiple system atrophy: A positron emission tomography study. Neurobiol Dis 2012; 46: 130-6.
54. Remy P, Doder M, Lees A et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervations in the limbic system. Brain 2005; 128: 1314-22. (Pubitemid 40826185)
55. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-63.
56. Jenkinson N, Nandi D, Muthusami K et al. Anatomy, physiology, and pathophysiology of the pendunculopontine nucleus. Mov Disord 2009; 24: 319-28.
57. Mesulam M, Mash D, Hersh L et al. Cholinergic innervation of the human striatum, globuspallidus, subthalamic nucleus, substantianigra and red nucleus. J Comp Neurol 1992; 323: 252-68.
58. Kuhl DE, Koeppe RA, Fessler JA et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994; 35: 405-10. (Pubitemid 24079964)
59. Kuhl DE, Minoshima S, Fessler JA et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996; 40: 399-410. (Pubitemid 26304797)
60. Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. Arch Neural 2003; 60: 1745-8. (Pubitemid 37521630)
61. Hilker R, Thomas AV, Klein JC et al. Dementia in Parkinson's disease. Functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-22.
62. Bohnen NI, Kaufer DI, Hendrickson R et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242-7. (Pubitemid 43255898)
63. Shimada H, Hirano S, Shinotoh H et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-8.
64. Gilman S, Koeppe RA, Nan B et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010; 74: 1416-23.
65. Asahina M, Shinotoh H, Hirayama K et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 1995; 91: 437-43.
66. Asahina M, Suhara T, Shinotoh H et al. Brain muscarinic cholinergic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998; 65: 155-63. (Pubitemid 28371923)
67. Fujita M, Ichise M, Zoghbi SS et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 2006; 59: 174-7. (Pubitemid 43042884)
68. Oishi N, Hashikawa K, Yoshida H et al. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT. J Neurol Sci 2007; 256: 52-60. (Pubitemid 46560626)
69. Kas A, Bottlaender M, Gallezot JD et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cerebr Blood Flow Metabol 2009; 29: 1601-8.
70. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
71. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
72. Long-Smith CM, Sullinan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009; 89: 277-87.
73. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 2010; 117: 971-9.
74. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006; 80: 308-22. (Pubitemid 46107737)
75. Papadopoulos V, Baraldi M, Guilarte TR et al. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-9. (Pubitemid 44069585)
76. Ouchi Y, Yoshikawa E, Sekine Y et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-75. (Pubitemid 40179853)
77. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-12.
78. Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009; 15Suppl 3: S200-4.
79. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 2010; 16: 57-9.
80. Scarf AM, Kassiou M. The translocator protein. J Nucl Med 2011; 52: 677-80.
81. Iwanaga K, Wakabayashi K, Yoshimoto M et al. Lewy body-type degeneration in cardiac plexus in Parkinson's disease and incidental Lewy body diseases. Neurology 1999; 52: 1269-71. (Pubitemid 29177934)
82. Arimo T, Orimo S, Itoh Y et al. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005; 15: 29-34. (Pubitemid 40224064)
83. Orimo S, Uchihara T, Nakamura A et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008; 131: 642-50. (Pubitemid 351294710)
84. Fujishiro H, Frigerio R, Burnett M et al. Cardiac sympathetic denervation correlates with clinical and pathological stages of Parkinson's disease. Mov Disord 2008; 23: 1085-92.
85. 123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1995; 53: 230-4.
86. 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 1998; 19: 137-42.
87. 123I-MIBG uptake in Parkinson's disease. ActaNeurolScand 1998; 97: 303-6.
88. 123I] iodobenzylguanidine in Parkinson's with autonomic failure. Acta Neurol Scand 1998; 97: 307-14.
89. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371-5.
90. 123I-metaiodobenzylguani- dine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-94.
91. Druschky A, Hitz MJ, Platsch G et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000; 175: 3-12. (Pubitemid 30227477)
92. Reinhardt MJ, Jóngling FD, Krause TM, Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000; 27: 595-600. (Pubitemid 30262627)
93. Takatsu H, Nishida H, Matsuo H et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000; 41: 71-7. (Pubitemid 30046686)
94. Taki J, Nakajima K, Hwang EH et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27: 566-73. (Pubitemid 30262623)
95. Spiegel J, Mφllers MO, Jost WH et al. FP-CIT SPECT and MIBG scintigraphy in early Parkinson's disease. Mov Disord 2005; 20: 552-61.
96. Kajimoto Y, Miwa H, Okawa-Izawa M et al. Transcranial sonography of the substantianigra and MIBG myocardial scintigraphy: complementary role in the diagnosis of Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 270-2.
97. Izawa MO, Miwa H, Kajimoto Y, Kondo T. Combination of transcranial sonography, olfactory testing and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease. Eur J Neurol 2012; 19: 411-6.
98. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-7. (Pubitemid 28141060)
99. Matsui H, Nishinaka K, Oda M et al. Does cardiac mataiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006; 12: 284-8. (Pubitemid 43816337)
100. Kim JS, Lee KS, Song IU et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci 2008; 270: 122-6.
101. 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 423-6.
102. 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 2004; 220: 105-11.
103. Nagayama H, Hamamoto M, Ueda M et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-51. (Pubitemid 40143717)
104. Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007; 22: 1004-8. (Pubitemid 46999298)
105. Chung EJ, Kim EG, Kim MS et al. Differences in myocardial sympathetic degeneration and the clinical features of the subtypes of Parkinson's disease. J Clin Neurosci 2011; 18: 922-5.
106. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-5.
107. 123I-MIBG cardiac scintigraphy. Parkinsonism Relat Disord 2012; 18: 45-8.
108. Courbon F, Brefel-Courbon C, Thalamas C et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-7. (Pubitemid 37021163)
109. Oka H, Mochio S, Onouchi K et al. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 2006; 241: 59-65. (Pubitemid 43112517)
110. 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006; 47: 1099-101.
111. 123I)metaiosobenzylguan idinescintigraphy for vascular Parkinsonism. Mov Disord 2006; 21: 1990-4.
112. Braune S. The role of cardiac metaiodobenzylguanidine in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11: 351-5. (Pubitemid 34461714)
113. 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy-body-related disorders. MovDisord 2011; 26: 1218-24.
114. Treglia G, Stefanelli A, Cason E et al. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 2011; 113: 823-9.
115. Treglia G, Cason E, Stefanelli A et al. MIBG scintigraphy in differential diagnosis of parkinsonism: a meta-analysis. Clin Auton Res 2012; 22: 43-55.
116. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis. Parkinsonism Relat Disord 2012; 18: 494-500.
117. 123I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease. Hell J Nucl Med 2012; 15: 134-8.